テープストリップで皮膚疾患の免疫変化をマッピング(Mount Sinai Dermatologists Use Tape Strips to Map Immune Changes in Common Skin Disease)

ad

2025-06-10 マウントサイナイ医療システム (MSHS)

テープストリップで皮膚疾患の免疫変化をマッピング(Mount Sinai Dermatologists Use Tape Strips to Map Immune Changes in Common Skin Disease)

マウント・サイナイ医療センターの皮膚科チームは、28名の脂漏性皮膚炎(SD)患者を対象に、テープストリップ法を用いて免疫応答と脂質異常を解析しました。非侵襲的なこの方法で皮膚表層の細胞を採取し、RNAシーケンシングを実施。その結果、IL‑23/Th17およびTh22経路(例:IL23A, IL22, S100A8/12)が著しく活性化し、一部Th1(OASL, STAT1, CXCL9)も示され、Th2は控えめでした。同時に、バリア機能関連マーカー(CLDN1/8, FA2H, ELOVL3)はダウン調整されており、炎症とバリア異常が伴う分子プロファイルが明確に示されました。これはSDの病態理解を深め、IL‑23/Th17/Th22経路に着目した新たな免疫調整療法の開発に道を拓くものです。

<関連情報>

脂漏性皮膚炎患者におけるテープストリッププロファイリングによる免疫・脂質異常の同定 Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis

Benjamin Ungar, MD ∙ Meredith Manson, BA ∙ Madeline Kim, MD, MS ∙ … ∙ Diane Hanna, DNP ∙ Patrick Burnett, MD, PhD ∙ Emma Guttman-Yassky, MD, PhD
Journal of the American Academy of Dermatology  Published:February 1, 2025
DOI:https://doi.org/10.1016/j.jaad.2025.01.082

Abstract

Background

Seborrheic dermatitis (SD) is a common, chronic inflammatory skin disease with limited understanding of its pathophysiology. Molecular profiling has been limited by invasiveness of sampling methods.

Objective

To analyze the molecular skin profile of adult patients with SD using tape strips.

Methods

Tape-strips obtained from facial lesions of 26 adult SD patients and 18 demographically matched healthy controls were evaluated with RNA sequencing.

Results

SD molecular skin fingerprint was characterized by strong and significant upregulation of interleukin (IL)23/T-helper (Th)17 and Th22 (i.e. IL23A, IL22, PI3, LL37, S100A8, S100A12), some Th1 skewing (OASL, STAT1, CXCL9), and limited Th2 modulation. A parallel downregulation of barrier markers (CLDN1/8, FA2H, ELOVL3) was also observed.

Limitations

Limited representation of mild and severe SD patients.

Conclusion

These data deepen our understanding of SD suggesting that it has robust Th17/Th22, some Th1 skewing, and minimal Th2 activation, and associated skin barrier alterations. This provides rationale for novel immunomodulatory treatment approaches for SD patients targeting IL23/Th17 and/or Th22 pathways.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました